Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or stalls.

Many organizations enter the scaling phase still relying on finance models built for survival. These models lack the structure, visibility, and control required to support growth, especially as investor expectations rise and competition intensifies.

Building a comprehensive financial foundation early in the lifecycle addresses the structural challenges that prevent life sciences companies from scaling effectively and positions finance as a driver of long-term success. A modern, technology-enabled finance function gives leaders real-time insight, supports strategic decision-making and scales with the business – allowing executive and leadership focus to remain on the vision and mission, to support sustainable growth and best-in-class innovation.

The challenge: Moving beyond survival, into scaling with oversight and control

Whether focused on professional services, pharmaceuticals, medical devices, or durable products, life sciences organizations face a unique combination of operational and technical pressures that strain early-stage financial systems.

• • Due to the length of R&D and trial phases, many companies operate without a product on the market and without customers paying for services. The business runs entirely on capital raised, making every dollar of financial burn a strategic decision that must be tracked with precision.
  • Revenue streams are often intermittent. Funding arrives through grants, investor closes, or milestone achievements, forcing finance teams to plan around uncertain timing rather than consistent monthly inflows.

These realities create a constant need for precise cash visibility and disciplined planning. Yet many early finance functions rely on spreadsheets, disconnected tools, and manual workflows, and manual aggregation becomes a recurring burden that lean finance teams cannot reliably absorb. Leadership is left without the current financial picture needed to make timely decisions about spending, hiring, and fundraising. 

The problem tends to compound as life sciences companies grow and demands on finance increase exponentially. Stakeholders expect timely, accurate reporting and forward-looking visibility.

• • Cash runway becomes the most consequential metric in a capital-dependent business.
  • Preparing for institutional investment, strategic partnerships, or commercialization requires clean, defensible documentation that can withstand scrutiny. 
  • Diligence timelines are rarely generous, and disorganized records can derail progress at critical moments.

As companies advance through clinical phases or prepare for commercialization, transaction volume increases. Higher headcounts, more vendors, and more clinical activity create more financial activity flowing through the system. Manual processes quickly fall behind, creating backlogs of unreconciled items that compound each month.

Without scalable infrastructure, these complexities overwhelm internal teams. Early-stage teams are often small, with little spare bandwidth for strategic work or process improvement, resulting in a finance function that works hard but struggles to scale. When finance cannot scale, the entire organization feels the impact.

The solution: A modern, technologically enabled finance function

A scalable finance model integrates systems, processes, automation, and expertise to support daily operations and long-term strategies.

Cloud-native general ledgers provide an accessible, AI-powered financial source of truth. They eliminate version-control issues and scale with the business.

Reporting platforms connected directly to the accounting system allow teams to build multi-scenario financial models without manual data transfers. Actuals flow automatically into forecasts, eliminating hours of manual input.

Digitizing purchase orders, invoice approvals, and payment processing reduces time spent on routine transactions, enforces spending controls, and creates an auditable record of commitments and payments.

Purpose-built dashboards give leadership real-time visibility into cash position, departmental spend, and projected runway under multiple assumptions. Executives can act on current information rather than outdated figures. These tools reduce manual work, improve accuracy, and strengthen decision-making.

A structured control framework makes sure no single individual can initiate, approve, and record a transaction without independent review. As the organization grows, system-based controls scale with it, adding approval layers and oversight as complexity increases. Controls never lag behind the business they are designed to protect.

A solid financial foundation enables sustainable growth

• • Companies that modernize their finance function experience measurable benefits:
  • Leadership gains the ability to model funding scenarios, hiring plans, and trial timelines with confidence. 
  • Capital allocation decisions are based on current data rather than outdated estimates, reducing the risk of misaligned investment.
  • Timely, accurate reporting strengthens credibility with investors, shortens diligence cycles, and reduces friction during fundraising.
  • Automation accelerates the close cycle, reporting cycle, and transaction processing.
  • The finance function operates faster and at lower long-term cost because fewer hours are spent on tasks that systems can perform more efficiently.

With scalable infrastructure in place, organizations can move quickly as trials expand, commercialization approaches, or partnership and M&A opportunities arise. They avoid the delays and costs associated with fixing the finance function under pressure.

CohnReznick’s life sciences accounting

Life sciences companies cannot afford a reactive finance function. Modernization is foundational to growth.

A technology-enabled, outsourced accounting and advisory model provides the expertise, scalability, and visibility required to operate confidently in a complex industry.

An outsourced accounting provider can expand services as the company moves from post-seed to Series A to late-stage funding, eliminating the need to recruit and onboard internal hires in a talent market where experienced life sciences finance professionals are scarce and expensive. This model maintains financial rigor without overextending internal resources, and further reduces risk and supports audit readiness.

Contact CohnReznick’s life sciences accounting professionals for support in building the financial infrastructure you need – so you can focus on advancing scientific innovation and building a successful business.